Bitcoin 220.84
$8,869.27 2.49%
Ethereum 17.73
$233.27 7.6%
Zcash 3.85
$53.82 7.16%
Monero 2.73
$71.02 3.85%
Tether 0.00
$1.00 0.11%
Stellar 0.00
$0.06 6.4%
Future of Healthcare Innovation

CRPT Rating: 2.1

  • Team & Advisory Board
  • Product & Research
  • Idea
  • Marketing
  • Investors Security
View Detailed Rating Website Whitepaper

Founded in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high quality companies in the U.S. and China. With more than $1.7 billion under management, Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Shanghai, and Beijing, China. At Vivo Capital, we leverage our internal expertise in evaluating data to generate outsized returns for company founders and employees as well as for our investors. Vivo invests primarily in later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China. Vivo assists its portfolio companies in both countries in forging cross-border partnerships, enabling the companies to acquire new products and expand the market for their existing products. In addition to making investments in existing companies, Vivo also builds companies from scratch to pursue compelling opportunities together with experienced management teams. Finally, a portion of every Vivo fund is invested directly into public therapeutics companies. Despite its focus on companies with later-stage products, Vivo is willing to work with companies (and their founders) that may not have significant infrastructure. We invest in companies with promising products at all financing stages (Series A to public companies), and work closely with founders and management to complete the development and commercial launch of those products and achieve a successful exit.

Token Sale: 16 October — 31 December
Ticker
ICO Token Price
Whitelist
Min/Max Personal Cap
Accepts
Softcap
Hardcap

CRPT Rating (?) : 2.1


  • Team & Advisory Board
    • TEAM (2.2)
      • Leading Technological Experts (2)
      • Project Leader (3)
      • Development Team lead (2)
      • Marketing Lead (2)
      • Specification of experts work (3)
      • Experts Experience of in their spheres (2)
      • Presence of all necessary experts (2)
    • Advisory Board (2.0)
      • Popularity of advisors (2)
      • Expertise of advisors to the project profile (2)
  • Product Description & Marketing Research
    • Product Description (2.4)
      • Roadmap (2)
      • Detalization of product description (3)
      • Regularity of github commits (3)
      • Presence of product beta version (2)
      • Token description and role (2)
      • Discounts on goods and services (2)
      • Possibility of the project management via dao (2)
      • Devidents reception from tokens (2)
      • Buyout of tokens from investors (1)
      • Commision for tokens usage (1)
      • Profit calculation is present and adequate (3)
      • Financial plan detalization (2)
      • Tokens spending ratio (3)
    • Marketing Research (2.7)
      • Lack of competitors (2)
      • Lack of ready made products (3)
      • Presence of technological advantages (2)
      • The amount of financing attracted by competitors (3)
      • Dynamics of competitors growth (2)
      • Jurisdiction research (3)
      • Legal disclaimer for duties and obligations (3)
  • Idea (2.2)
    • Adequacy of the idea (1)
    • Originality of the idea (3)
    • Value of the idea for the community (3)
  • Marketing (2.0)
    • Website (3)
    • Social networks (2)
    • Marketing plan (3)
    • Marketing team (1)
    • Public presence of the team (1)
  • Investors Security (1.4)
    • Daico (1)
    • Decentralized escrow (2)



Short review
Number of team Members
Prototype

Add a Comment

Member of The Internet Defense League